Adenine Base Editing In Vivo with a Single Adeno-Associated Virus Vector
GEN Biotechnology · 2022
DOI: 10.1089/genbio.2022.0015 ↗Kurz gefasst
Fachartikel in der Zeitschrift GEN Biotechnology, 2022. Verfasst von Han Zhang und 13 weiteren Autor:innen. Beteiligte Einrichtung: RNA Therapeutics Institute, University of Massachusetts Chan Medical School, Worcester, Massachusetts, USA. Die Arbeit wurde bisher 64-mal zitiert (Crossref) und nennt 87 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIGMS NIH HHS.
Abstract (Originalsprache)
Base editors (BEs) have opened new avenues for the treatment of genetic diseases. However, advances in delivery approaches are needed to enable disease targeting of a broad range of tissues and cell types. Adeno-associated virus (AAV) vectors remain one of the most promising delivery vehicles for gene therapies. Currently, most BE/guide combinations and their promoters exceed the packaging limit (∼5 kb) of AAVs. Dual-AAV delivery strategies often require high viral doses that impose safety concerns. In this study, we engineered an adenine base editor (ABE) using a compact Cas9 from Neisseria meningitidis (Nme2Cas9). Compared with the well-characterized Streptococcus pyogenes Cas9-containing ABEs, ABEs using Nme2Cas9 (Nme2-ABE) possess a distinct protospacer adjacent motif (N 4 CC) and editing window, exhibit fewer off-target effects, and can efficiently install therapeutically relevant mutations in both human and mouse genomes. Importantly, we show that in vivo delivery of Nme2-ABE and its guide RNA by a single AAV vector can efficiently edit mouse genomic loci and revert the disease mutation and phenotype in an adult mouse model of tyrosinemia. We anticipate that Nme2-ABE, by virtue of its compact size and broad targeting range, will enable a range of therapeutic applications with improved safety and efficacy due in part to packaging in a single-vector system.
Autor:innen und Institutionen
- RNA Therapeutics Institute, University of Massachusetts Chan Medical School, Worcester, Massachusetts, USA.
- Departments of Molecular, Cell and Cancer Biology, University of Massachusetts Chan Medical School, Worcester, Massachusetts, USA.
- Departments of Biochemistry and Molecular Biotechnology, University of Massachusetts Chan Medical School, Worcester, Massachusetts, USA.
- NeuroNexus Institute, University of Massachusetts Chan Medical School, Worcester, Massachusetts, USA.
- Horae Gene Therapy Center, University of Massachusetts Chan Medical School, Worcester, Massachusetts, USA.
- Viral Vector Core, University of Massachusetts Chan Medical School, Worcester, Massachusetts, USA.
ORCID-Profile: Nathan Bamidele, Ogooluwa Ojelabi, Tomás Rodriguez, Haoyang Cheng, Erik J Sontheimer
Förderung
- NIGMS NIH HHS
Zitieren
APA
Zhang, H., Bamidele, N., Liu, P., Ojelabi, O., Gao, X. D., Rodriguez, T., Cheng, H., Kelly, K., Watts, J. K., Xie, J., Gao, G., Wolfe, S. A., Xue, W., & Sontheimer, E. J. (2022). Adenine Base Editing In Vivo with a Single Adeno-Associated Virus Vector. GEN Biotechnology. https://doi.org/10.1089/genbio.2022.0015
Vancouver
Zhang H, Bamidele N, Liu P, Ojelabi O, Gao XD, Rodriguez T, et al. Adenine Base Editing In Vivo with a Single Adeno-Associated Virus Vector. GEN Biotechnology. 2022. doi:10.1089/genbio.2022.0015
BibTeX
@article{Zhang2022,
author = {Zhang, Han and Bamidele, Nathan and Liu, Pengpeng and Ojelabi, Ogooluwa and Gao, Xin D and Rodriguez, Tomás and Cheng, Haoyang and Kelly, Karen and Watts, Jonathan K and Xie, Jun and Gao, Guangping and Wolfe, Scot A and Xue, Wen and Sontheimer, Erik J},
title = {Adenine Base Editing In Vivo with a Single Adeno-Associated Virus Vector},
journal = {GEN Biotechnology},
year = {2022},
doi = {10.1089/genbio.2022.0015}
}
EUVIMED